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Introduction
Fabry disease is a lysosomal storage disorder caused by deficient lysosomal α-galactosidase A (α-Gal A, EC 3.2.1.22) activity, resulting in progressive accumulation of neutral glycosphingolipids in vascular endothelial cells [1] . This disorder is classified into two major subtypes based on clinical manifestations. Patients with classic early onset Fabry disease show various clinical symptoms, such as angiokeratoma, acroparathesis, hypohidrosis, corneal and lenticular opacities, and progressive vasculopathy of the kidney, heart, and central nervous system. In contrast, atypical variants with residual α-Gal A activity show late onset cardiomyopathy with left ventricular hypertrophy but not the classic symptoms [2] .
Currently, enzyme replacement therapy (ERT) is the only approved therapy for Fabry disease [3, 4] .
ERT has been well-tolerated by patients, as characterized by improvement in gastrointestinal and neurological manifestations (acroparaesthesia, hypohidrosis, vasomotion) and in quality of life [5, 6] .
However, results from treating variant Fabry disease patients have been mixed, suggesting that ERT may be inefficient for treating severe late-stage patients, presumably as a result of insufficient delivery of the enzyme to particular tissue [7, 8] . ERT is expensive, and it could therefore be an economic burden for patients, so it is necessary to develop alternative affordable therapies for treating patients with Fabry disease.
We have shown that residual enzyme activity in lymphoblasts established from atypical Fabry patients with R301Q or Q279E mutations can be increased by cultivating cells with
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ACCEPTED MANUSCRIPT 5 1-deoxygalactonojirimycin (DGJ), a potent competitive inhibitor of α-Gal A [9] . We designated our therapeutic strategy as active-site-specific chaperone (ASSC) therapy because we hypothesized that DGJ binds to the active site of the enzyme, works as a folding template of misfold proteins, and enhances the enzyme activity [10, 11] . Our recent study showed that the majority of missense mutant enzymes, identified in patients with residual enzyme activity, retain the catalytic activity and fragile conformation resulting in excessive degradation of affected mutant protein in endoplasmic reticulum-associated degradation (ERAD). This is the main molecular cause for the deficiency of the protein and broadness of the DGJ effect in the treatment of both classic and variant Fabry patients with residual enzyme activity [12] . We proposed that DGJ acts for those mutant proteins with a fragile conformation to facilitate proper folding, thus avoiding retardation and excessive degradation of these mutant enzymes in the endoplasmic reticulum (ER) [13] .
To prove our hypothesis, in this study we focused on the behavior of mutant α-Gal A in the ER of mammalian cells and provided the evidence that DGJ acts in the ER. To determine the manner of degradation of mutant α-Gal A in the ER and the enhancement of enzyme activity of mutant α-Gal A by the treatment of DGJ in the ER, we used in vitro translation, translocation, and cells cultured in the presence of brefeldin A, which is an inhibitor of transport from the ER to the cis-Golgi [14, 15] . We also provided the evidence that the majority of mutant α-Gal A was retained in the ER when it was expressed in COS-7 cells, whereas, in contrast, the rescued mutant α-Gal A by the treatment of DGJ was mainly located in lysosomes. [19] , according to the manufacturer's protocol. Rough microsomes (RM) containing synthesized proteins were sedimented by centrifugation for 5 min at 100,000 x g through a cushion of 50 mM triethanolamine (TEA) (pH 7.4) buffer containing 0.5 M sucrose and 1 mM dithiothreitol (DTT).
Resulting vesicles were subjected to trypsin digestion or endoglycosidase H (Endo H, New England Biolabs) digestion as follows. Trypsin (25 μg/ml) was added to RM in the presence of 1% Triton X-100.
Following incubation for 10 min on ice, the reaction was terminated by the addition of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (50 mM Tris-HCl buffer, pH 6.8, containing 2% SDS, 10% glycerol, 0.01% bromophenol blue, and 3% 2-mercaptoethanol). Endo H digestion was carried out according to manufacturer's protocol (CALBIOCHEM, San Diego, CA). For the degradation assay, the vesicles were washed with a high salt buffer (0.5 M potassium acetate, 5 mM magnesium acetate) and subjected to ultracentrifugation through a 0.5 M sucrose cushion to remove the reticulocyte lysates. The isolated vesicles were resuspended in a chase buffer (20 mM HEPES, pH 7.5, 50 mM KCl, 1 mM CaCl 2 ) and incubated with or without 20 μM DGJ at 37 o C for 0.5, 1, 2, and 4 h. Each vesicle was subjected to SDS-PAGE and quantified by a BAS 2000 phosphoimage analyzer (Fuji Film, Tokyo, Japan). A-sepharose CL-4B (GE Healthcare Bio-Sciences) were then added to the supernatants from medium and cell lysates for immunoprecipitation, which was carried out with a slight modification as previously reported [20] . The immunoprecipitates were briefly washed five times in a washing buffer (25 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 0.1% Triton X-100 and 0.1% SDS) to remove nonspecifically absorbed protein. Bound antigen was eluted from the beads by boiling in SDS-PAGE sample buffer and then analyzed by SDS-PAGE. The gels were quantified in the BAS 2000 phosphoimage analyzer.
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Enzyme assay and protein determination. α-Gal A activity was assayed with 4-methylumbelliferyl α-D-galactopyranoside (4MU-α-Gal, Sigma Chemicals) as a substrate, as described previously [18] .
One unit of enzyme activity was defined as the amount of enzyme that releases 1 nmol of 4-methylumbelliferone per hour. Protein concentration was determined using a DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA) with bovine serum albumin (BSA, Sigma Chemicals) as a
Western blot analysis. Western blot analysis for the detection of α-Gal A protein was performed using polyclonal anti-α-Gal A antibody and HRP-conjugated anti-rabbit IgG antibody as described previously [18] . Immunoelectron microsopy. The COS-7 cells expressing wild-type or R301Q α-Gal A were cultured with or without 20 μM DGJ for 48 h after transfection, then fixed in 2% glutaraldehyde in 0.2 M Tris-HCl (pH 7.4) for 3 h; and further incubated in 1% osmium tetraoxide for 2 h, dehydrated in ethanol, and embedded in Epok 812. Immunoelectron microscopy was performed as described previously [21] .
Thin sections were briefly microwaved in Target Retrieval Solution, pH 10 (DAKO, Carpinteria, CA), and then incubated for 30 min at room temperature with affinity purified anti-α-Gal A antibody diluted
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ACCEPTED MANUSCRIPT 10 1:50. After washing with 50 mM Tris-HCl (pH 7.5) containing 0.8% NaCl, 0.1% BSA, and 0.1% Tween 20, the ultrathin sections were incubated with gold-conjugated goat anti-rabbit IgG. After washing, the ultrathin sections were stained with uranyl acetate and lead citrate, and examined using a transmission electron microscope (JEM-1200EXII, JEOL, Japan).
Results
In order to examine the stability of R301Q in the ER, we established the in vitro translation and translocation system using rabbit reticulocyte lysates and canine pancreas RM. The α-Gal A was synthesized as a single product 46-kDa polypeptide by translation with reticulocyte lysates ( were observed in the incorporated products into RM. All bands incorporated into RM were sensitive to Endo H, which removes high-mannose type oligosaccharides from glycoproteins; and as a result, were shifted to an approximate 43-kDa band after Endo-H treatment (Fig. 1A, lane 7) . From the trypsin-treatment with or without Triton X-100, we demonstrated that this in vitro system is well functioning, and suggested that α-Gal A is properly translocated and processed as previously described
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11 for other proteins [22, 23] . There was no difference between wild-type and R301Q α-Gal A on the profiles and in the efficiency of the translation, translocation, and glycosylation from the same amount of transcripts. The amount of 50-kDa polypeptide of wild-type and R301Q α-Gal A was 33% and 36%, respectively, of the total product. To study the stability of the protein product from an in vitro translation and translocation system, the microsomal vesicles containing R301Q or wild-type α-Gal A were pooled and further incubated. Two minor bands other than the 50-kDa band were decreased within 4-h chase in both wild-type and R301Q. Although the 50-kDa band was remained in wild-type during 4-h chase, the 50-kDa band of R301Q was decreased in this treatment (Fig. 1, B and C). These data suggest that R301Q is unstable in the microsomal vesicles, and this instability may cause low enzyme activity in patients' cells. The addition of DGJ had no effect on the degradation of R301Q in this cell-free system (data not shown). To confirm further that R301Q was degraded by ERAD, the effect of lactacystin, which is an inhibitor for proteasome (ERAD) [24] on the degradation of R301Q in TMK2 cells was studied ( Fig. 1, D) . Pulse-labeled R301Q was markedly degraded within a 2-h chase period, but it was blocked by the treatment with lactacystin.
To identify the cellular compartment in which the effect of DGJ on R301Q occurred, the pulse-chase experiment using TMK2 cells was carried out in the presence of brefeldin A, which is a transport inhibitor causing retention of newly synthesized membrane proteins and secretory proteins in the ER [25, 26] . As shown in Figure 2 , R301Q pulse-labeled with [ 35 S]-Met/Cys was substantially reduced within a 2-h chase period in the presence of brefeldin A, whereas the wild-type α-Gal A was not changed during brefeldin A did not protect the degradation of R301Q at all, presumably due to the inhibitory effect of brefeldin A on the DGJ import into the ER. These data suggest that R301Q is degraded by ERAD and that DGJ acts in the ER to restore R301Q.
To elucidate the change in enzyme activity of R301Q in the ER, we used a transient expression system because stable transformants such as TMK2 cells are not suitable when we selectively determine the activity of newly synthesized protein. Wild-type or R301Q α-Gal A was transiently expressed in COS-7 cells and kept in their ER by treatment with brefeldin A for 24-48 h after transfection. In the expression system using COS-7 cells, recombinant α-Gal A was transiently synthesized after 24 h of transfection, and the enzyme activity and amount rapidly increased during this time. Therefore, newly synthesized enzymes were retained in the ER by the treatment with brefeldin A, and the effect of DGJ on the activity of newly synthesized proteins could be examined. The enzyme activity in COS-7 cells expressing R301Q (202 ± 12 nmol/h/mg protein) was almost the same level as mock transfected COS-7 cells (168 ± 5 nmol/h/mg protein) and was much lower than cells expressing wild-type α-Gal A (4380 ± 160 nmol/h/mg protein) (Fig. 3) . The pretreatment of those cells with DGJ allowed a significant increase to be selectively observed in cells expressing R301Q (1740 ± 176 nmol/h/mg protein), which was approximately 50% of the level in cells expressing wild-type α-Gal A treated with DGJ and brefeldin A (3700 ± 765 nmol/h/mg protein). The enzyme amount detected by Western blot analysis was high in
13 cells expressing wild-type α-Gal A and DGJ-treated cells expressing R301Q. These data indicated that the degradation of R301Q was related to its enzyme activity; and enzymes that lost their activity could be recognized by the ERAD in mammalian cells.
To verify the distribution of R301Q in transfected COS-7 cells, immunoelectron microscopic study was conducted with anti-α-Gal A antibody (Fig. 4) . Although it is a little hard to distinguish ribosomes (20 nm) from gold particles (15 nm, clear dots) at lower magnification, it is much easier at higher magnification. After we applied the modified technique [21] to prepare the specimens, the COS-7 cells expressing R301Q revealed gold particles predominantly in the ER surrounding the nucleus (Fig. 4, A-C). In contrast, gold particles were observed mainly in the lysosomes but could not be detected in the ER in cells expressing R301Q treated with DGJ for 48 h (Fig. 4, D-F) , and there was a similar pattern for cells expressing wild-type α-Gal A (data not shown). To determine the relative amount of R301Q localized in the lysosomes, we counted the whole number of gold particles in 50 independent cells and calculated a percentage of gold particles located in the lysosomes. Almost of all gold particles (represents α-Gal A) were detected in lysosomes and the ER, and the ratio of R301Q localized in lysosomes and the ER was 6:94 in the absence of DGJ, but it was changed to 79:21 in the presence of DGJ, and it became similar to that of wild-type α-Gal A (82:18), implying that R301Q rescued by DGJ in the ER was normally processed and sent to its final destination, the lysosomes.
Discussion
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In this study, we established an in vitro translation and translocation assay for studying human α-Gal A and observed some characteristics of R301Q in the ER. The in vitro translated product (approximately 46-kDa) had a similar size as that predicted from the 429-amino acid precursor sequence of α-Gal A [27] . The translocated protein (50-kDa band) appeared when in vitro translation was performed in the presence of canine pancreas RM. This protein, recovered in RM sedimented by centrifugation, had a resistance to trypsin-digestion, and it was characterized as the precursor-form of α-Gal A translocated into RM. The size of precursor-form α-Gal A was identical to that observed in mammalian cells [12, 28] . The Endo H-digestion of the 50-kDa protein strongly suggested that it was glycosylated. The difference in size between the 50-kDa precursor protein and digested product (43 kDa) was approximately 7 kDa, which is equal in size to 3 units of N-glycan (about 2.4 kDa). The product of our in vitro translation and translocation system may be fully glycosylated because 3 sites were glycosylated with a recombinant human α-Gal A expressed in mammalian cells [29] . Furthermore, the 3-kDa difference between the in vitro translated product and Endo H-digested product (43-kDa) was equal to the size predicted from the signal sequence containing 31 amino acids [27] . Two minor bands (48-kDa and 46-kDa bands) translocated into RM may be 2 units and single unit, respectively, of N-glycan-binding products, and these minor bands of both wild-type and R301Q were unstable in the microsomal vesicles. We feel that all of the above data indicate that mutant α-Gal A, as well as wild-type protein, was normally translated, translocated, and glycosylated in our cell-free system.
Although there was no difference between wild-type and R301Q α-Gal A in the process of
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15 translation, translocation and glycosylation, they could be distinguished on the basis of their stability.
R301Q was rapidly degraded in microsomal vesicles (Fig. 1B) , while α-Gal A was found to be stable.
The stability of R301Q in the ER may be the crucial factor which causes its low activity in patients'
cells.
The addition of DGJ in this cell-free system did not show any protective effect on this degradation, which may be due to the inaccessibility of DGJ to R301Q in this system. Although we do not have any data on the transport of DGJ, we predicted that DGJ would be taken up by cells through other iminosugar derivatives like 1-doxymannojirimycin (dMM) because of their structural similarity.
Neefjes et al. [30] have reported that uptake of dMM by human erythroleukemic cells was not inhibited by glucose, and it (and other iminosugars) may not be carried into cells by hexose transporters [31] .
They also discussed the presence of the translocation system for dMM in cells because passive diffusion of dMM cannot explain the difference of the Ki value (80 μM) of dMM for isolated mannosidase and the concentration (1 mM) of dMM necessary to inhibit mannosidase in cells. The presence of two distinct mannose transporters which are dMM-sensitive and insensitive had been reported in intestinal epithelial cells [32, 33] . If dMM were incorporated into cells through glucose transporter GLUT4, it might be affected by the treatment with brefeldin A [34] . The data in our present study supported the presence of a translocation system for DGJ into the ER; pretreatment of DGJ prior to brefeldin A-treatment was necessary for showing the protective effect against R301Q degradation. We used a pulse-chase technique on TNK and TMK2 mouse fibroblasts cultured in the presence of brefeldin A (Fig. 2) , so that
16 newly synthesized enzymes were retained in the ER and their stability in the ER could be observed. The pulse-labeled R301Q quickly degraded within a 2-h chase period, but wild-type α-Gal A did not change.
The pretreatment of DGJ for 12 h prior to brefeldin A-treatment was necessary for the protective effect of DGJ on the degradation of R301Q. Therefore, transport of DGJ into the ER must be required to have an effect on R301Q. DGJ protected against not only the degradation of R301Q, but also the loss of enzyme activity (Fig. 3) .
In our previous paper [12] , we described that majority of enzyme mutants, which were detected in
Fabry patients who display residual activity, were thermolabile proteins in a solution at neutral pH, and degraded in ERAD because the amount of protein was increased by treatment with kifunensine, a selective inhibitor of ER α-mannosidase I and lactacystin (a proteasome inhibitor) [35] . In the present study, we confirmed the effect of lactacystin on R301Q-degradation by using R301Q-expressing murine fibroblasts (Fig. 1D) . Its effect had previously been observed in some mutant α-Gal A's such as E66Q, F113L, N215S, M296I, and R301Q, which were transiently expressed in COS-7 cells. [12] Several chaperones such as BiP and calnexin are known to exist in the ER [36] , and BiP might be a strong candidate as a molecular sensor, since it is associated with only R301Q but not wild-type proteins [37] or other misfolded proteins [38] . Recently, it has been postulated that ER degradation enhancing α-mannosidase-like protein (EDEM) or the EDEM family sequesters ERAD candidates released from calnexin, thereby interfering with the UDP-Glc:glycoprotein glucosyltransferase that reglucosylates misfolded glycoproteins released from the calnexin cycle [39, 40] . Although the molecular mechanism of recognizing misfolded α-Gal A's to be degraded in the ER is still unclear, we may be able to shed some light on this area by using mutant enzyme R301Q as a good model of misfolded proteins.
The addition of DGJ changed the localization of R301Q from the ER to lysosomes (Fig. 4) .
Although Yam et al. [37] reported that rescued R301Q by DGJ treatment was located in the lysosomes in fibroblasts established from transgenic mice [16] (as observed by immunoelectron microscopy), we further demonstrated its localization in lysosomes in COS-7 cells expressing R301Q in the presence of DGJ. COS-7 cells were established from monkey kidney cells [41] , and the kidney is one of the target organs for the treatment of Fabry disease. In our present study, we demonstrated using immunoelectron microscopy that mutant α-Gal A (R301Q) was mainly located in the ER. These data strongly suggested that mutant α-Gal A was degraded by ERAD, and the enhancement of enzyme activity in ASSC therapy using DGJ was caused by restoration of R301Q in the ER and normalization of its movement to the lysosomes. It has been reported that lysosomal glycosphingolipids accumulation in fibroblasts from patients with Fabry disease was diminished by the treatment with DGJ [42] , and the data demonstrated that the rescued mutant protein could work after reached to the lysosomes. Our therapeutic strategy may be useful for many diseases, and positive results using our concept of therapeutic strategy have been reported for Gaucher disease [43, 44] , G M1 -gangliosidosis [45] , Tay-Sachs disease [46] , retinitis pigmentosa 17 [47] , and Pompe disease [48] .
In our present study, we demonstrated that mutant α-Gal A (R301Q) was retained and degraded in the ER; DGJ acted as a folding template in the ER and rescued R301Q from the loss of enzyme activity and degradation. Although the details of the degradation process of R301Q in the ER still remain to be clarified, our in vitro translation and translocation technique and use of cells treated with brefeldin A will be useful tools for studying the degradation process of misfolded proteins. 
